Full-Time
Senior Scientist
Analytical Development
Updated on 8/1/2026
Ipsen Global
5,001-10,000 employees
Global biopharma focused on specialty care
No salary listed
Dreux, France
Hybrid
Hybrid work is indicated.
 Biology & Biotech (1) |
|---|
Get referred to Ipsen Global
See people who can refer or advise you
- Five to eight years of experience in an equivalent pharmaceutical development position.
- Technical expertise in the development, validation, and transfer of physicochemical and/or biotechnological analytical methods applicable to oral and/or injectable pharmaceutical forms.
- Significant demonstrated experience managing complex projects and technologies in analytical development.
- Advanced knowledge of analytical techniques applied to pharmaceutical development of finished products, including oral forms, injectable forms, biological products, and proteins.
- Successful experience developing pharmaceutical products in Europe and the United States, including dossier submissions and effective contribution to subsequent inspections.
- Proficiency in project management techniques.
- Proficiency in Good Manufacturing Practices and current Good Manufacturing Practices.
- A minimum BAC+5 higher scientific education in chemistry, analyses, or drug control, such as Pharmacist, Engineer, or Master.
- Fluent English to interface effectively with English-speaking subcontractors or other Ipsen sites.
- Ability to work in a team and in a matrix environment.
- Independently perform and/or coordinate technical and scientific studies involving sensitive and strategic issues for the group, such as new product development, introduction of new technologies, process optimization, and method development.
- Contribute to continuous improvement, knowledge capitalization, and knowledge sharing within the area.
- Design and propose analytical development studies appropriate to each phase of preclinical and clinical development to support pharmaceutical product development and regulatory submissions, while determining the technical, organizational, and human resources required for success.
- Design assigned technical studies, perform them or oversee their execution, evaluate results, and communicate findings through study reports within defined timelines, expected quality standards, regulatory requirements, and cost constraints.
- Develop pharmaceutical product control methods at each phase of clinical development.
- Lead activities related to validation of control methods.
- Transfer pharmaceutical product control methods.
- Define and propose stability studies required at each phase of clinical development.
- Define and plan development studies conducted in the laboratory or through subcontracting.
- Define the control strategy for pharmaceutical products in oral or injectable forms.
- Supervise release testing of clinical batches.
- Propose and justify the strategy for conducting analytical development studies.
- Ensure the reliability of results, format and interpret findings, assess their impact, identify anomalies and potential nonconformities, and conduct necessary investigations and corrective actions.
- Participate in defining and implementing the make-versus-buy strategy and selecting subcontractors when necessary.
- Supervise technicians assigned to the studies when performed internally.
- Establish and monitor subcontracting for studies performed externally.
- Draft specific sections of regulatory dossiers, including Investigational Medicinal Product Dossiers, Investigational New Drug applications, New Drug Applications, and Marketing Authorisation Applications, and retain technical responsibility for the assigned studies.
- Propose and implement innovative, high-value solutions that may support patent filings.
- Develop new technologies, propose purchasing new equipment, and supervise its use and evolution.
- Monitor scientific and regulatory developments related to the activities.
- Contribute to developing a high level of expertise within the analytical team to enable rapid product development within the appropriate quality framework.
- Maintain close collaboration with existing group organizations in the area of activity.
- Ensure and maintain Good Manufacturing Practice compliance of the analytical laboratory.
- Represent the analytical laboratory in Chemistry, Manufacturing, and Controls project teams or interactions with entities external to Product Development.
- Serve as a recognized scientific expert and provide cross-functional scientific advice or act as a scientific referent when needed.
- Organize lessons learned within studies and projects.
- Propose and implement improvement initiatives.
- Promote the company's excellence culture within the department.
- Support the Analytical Development Director in improving processes and working methods within the department.
- Comply with applicable good practices, energy, environmental, health, and safety rules through site procedures.
- Apply and propose actions aligned with Ipsen's corporate social responsibility orientations.
- A third-cycle degree or PhD in chemistry, analyses, or drug control.
- Fluent French.
Ipsen is a global biopharmaceutical company that concentrates on specialty care, developing and marketing medicines for oncology, neuroscience, and rare diseases. Its products work by treating specific high-need conditions, ranging from historical diarrhea treatment Smecta to modern targeted therapies in cancer and neurological disorders. The company differentiates itself through a focused portfolio in niche therapeutic areas, growth via strategic acquisitions, and a long-standing family heritage that shaped its international expansion and IPO-driven capital for expansion. Its goal is to address unmet medical needs worldwide by providing effective therapies for patients with serious or rare conditions.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Boulogne-Billancourt, France
Founded
2005
Get referred to Ipsen Global
See people who can refer or advise you
Simplify's Take
What believers are saying
- Bylvay generated €180 million in 2025, up 32.5% year over year.
- Ojemda's EU assessment provides a reusable template for broader reimbursement submissions.
- Ipsen's specialty-care focus targets high-value, unmet-need markets with durable pricing power.
What critics are saying
- Bylvay's Phase III failure eliminates a biliary atresia expansion opportunity.
- Ojemda still faces country-by-country reimbursement fights after the EU clinical assessment.
- Ipsen's growth remains exposed to binary trial outcomes in concentrated therapeutic areas.
What makes Ipsen Global unique
- Founded in 1929, Ipsen focuses on oncology, rare disease, and neuroscience.
- Ipsen built specialty care through Smecta, Decapeptyl, and later global expansion.
- The company combines French heritage with international R&D and commercial operations.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Wellness Program
Flexible Work Hours
Hybrid Work Options
Remote Work Options
Paid Vacation
Company News
French pharmaceutical company Ipsen has announced that Beech Tree, which holds a 26.03% stake in the company's capital and 33.05% of voting rights, has received a waiver from the French Financial Markets Authority exempting it from filing a mandatory public tender offer. The waiver follows the transfer of Henri Beaufour's stake in Beech Tree to the Alasol Foundation. The transaction includes a governance agreement between Altawin, the Alasol Foundation and Beech Tree. Under the agreement, the Alasol Foundation has committed to holding its Beech Tree shares for at least 15 years and will not interfere in Beech Tree's management of its Ipsen stake. The agreement also establishes Altawin's veto rights and ensures continuity with the strategic direction set during Beaufour's lifetime.
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR. GlobeNewswire | Ipsen Pharma Yesterday at 11:00pm PDT * IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors * ITGA2 revealed as novel target of Ipsen's investigational antibody drug conjugate IPN60300, over-expressed across numerous solid tumor types * Preclinical data show potential of Ipsen's growing collection of investigational medicines, leveraging precision immuno-modulation to deliver differentiated anti-tumor activity PARIS, FRANCE, 18 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the presentation of new preclinical data across multiple early development programs currently in Phase I clinical trials, at the American Association of Cancer Research (AACR) congress. These latest data include an oral presentation for T cell activator (TCA) IPN01203 to be presented during the coveted New Drugs on the Horizon program session, highlighting the differentiated mode of action, activating Vβ6/Vβ10 T cells. These latest preclinical data will expand the growing evidence base, reinforcing the first-in-class potential of IPN01203 to improve outcomes where there are significant unmet needs for people living with solid tumors. Additionally, Ipsen revealed ITGA2 as the novel target for innovative antibody-drug conjugate (ADC) IPN60300, now in active Phase I evaluation. Preclinical findings showed pronounced over-expression of ITGA2 across multiple solid tumors - including pancreatic, gastric and colorectal cancers - with clear differential expression when compared to normal tissues. These results confirmed that IPN60300 binds specifically and with high affinity to ITGA2, enabling efficient internalization and accumulation of the exatecan payload. Further preclinical tumor model data showed dose-dependent anti-tumor activity and favorable tolerability, suggesting a promising first-in-class therapy with the potential to improve clinical outcomes. "These data presented at AACR exemplify our approach to early science, showcasing how we are harnessing precision immuno-modulation backed by the strength of preclinical data to advance next generation therapies where there are the highest unmet needs," said Mary Jane Hinrichs, SVP Early Development, Ipsen. "It's a privilege to see the growing transformative potential of these new modalities, paving the way for potential best- and first-in-class impact for people living with cancer." Underscoring the strength and promise of Ipsen's precision medicine approach, IPN01203 and IPN60300 combine precision targeting with innovative mechanisms of action with the aim of delivering strength of efficacy where few other treatments exist. About IPN01203 IPN01203 is a first-in-class T cell activator which selectively activates a group of Vβ6 T cells through the TCR and IL-15R pathways, enhancing their ability to recognize and target tumors. IPN01203 was generated by Marengo's Selective T Cell Activation Repertoire (STAR) platform, a multi-specific fusion protein library that targets specific TCR Vβ variants fused to different co-stimulate moieties to develop potent T cell activators. A Phase I/II dose escalation and expansion trial is ongoing. About IPN60300 IPN60300 is a first-in-class antibody-drug conjugate targeting the novel tumor antigen ITGA2 known to be overexpressed in many solid tumors, including pancreatic, gastric and colorectal cancers. This novel tumor antigen was identified using Foreseen' Biotechnology's high throughput, integrated translational proteomics, and artificial intelligence (AI)-powered screening platforms. Comprised of an ITGA2-targeting antibody, exatecan payload and innovative linker from Escugen Biotechnology's EZWi-Fit(TM), IPN60300 is optimally designed to allow for a wide therapeutic index, with potential for improved efficacy over standard of care as well as a favorable safety profile. A Phase I/II dose escalation and expansion trial is ongoing. About Ipsen Chinook Observer is a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Its pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Its teams in more than 40 countries and its partnerships around the world enable Chinook Observer to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com. | Ipsen Contacts | / | / | | Investors | / | / | | Henry Wheeler | [email protected] | +33 7 66 47 11 49 | | Khalid Deojee | [email protected] | +33 6 66 01 95 26 | | Media | / | / | | Sally Bain | [email protected] | +1 857 320 0517 | | Anne Liontas | [email protected] | +33 7 67 34 72 96 | | / | / | / | Disclaimers and/or forward-looking statements The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on ipsen.com. This is a paid placement. For further inquiries, please contact GlobeNewswire directly.
· Ipsen and ImCheck Therapeutics have entered into a definitive share purchase agreement. ImCheck’s shareholders will be eligible to receive a payment of EUR 350 million and downstream payments, for a total potential consideration of up to EUR 1 billion. · ImCheck Therapeutics is a private French biotechnology company pioneering next-generation immuno-oncology therapies. · EQT Life Sciences has backed ImCheck since 2017 and has provided comprehensive support beyond capital, at the board level.
Transaction follows Investment Grade ratings assignment from both S&P and Moody’s PARIS, FRANCE, 19 March 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a...
BAKX Therapeutics today announced it closed $25 million in a Series A fundraising led by AB Magnitude Ventures Group with Ipsen Pharma SA and Sherpa H